博拓生物(688767) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 was CNY 448.37 million, a decrease of 19.85% compared to the previous year[2] - Operating profit fell to CNY 50.05 million, down 74.12% year-over-year[2] - Net profit attributable to shareholders decreased to CNY 46.80 million, a decline of 72.39% from the previous year[2] - Net profit excluding non-recurring gains and losses was CNY 24.98 million, down 79.06% year-over-year[2] - Basic earnings per share dropped to CNY 0.32, a decrease of 72.17% compared to the previous year[2] Assets and Equity - Total assets at the end of the reporting period were CNY 2,539.21 million, a decrease of 2.42% from the beginning of the period[5] - Shareholder equity attributable to the parent company was CNY 2,369.02 million, down 1.68% from the beginning of the period[5] - The company's share capital increased by 40.00% due to the capitalization of capital reserves[8] Market Challenges - The decline in revenue was primarily due to increased tariffs affecting exports to the U.S. and intensified competition in the domestic market[5] Innovation and R&D - The company focused on innovation and quality improvement in its POCT products, leading to increased R&D expenses and employee stock plan costs[6]